- Home
- CSGP vs JAZZ Comparison
CSGP vs JAZZ Comparison
Compare CSGP & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSGP | JAZZ |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 16.1B |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CSGP | JAZZ |
|---|---|---|
| Price | $30.46 | $257.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $60.57 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 7.6M | 687.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.14 | ★ 7.17 |
| Revenue | $965,230,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $19.71 | $6.22 |
| Revenue Next Year | $12.40 | $7.68 |
| P/E Ratio | $211.29 | ★ $35.79 |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $25.89 | $110.26 |
| 52 Week High | $94.93 | $265.05 |
Technical Indicators
Market Signals| Indicator | CSGP | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 58.19 |
| Support Level | $28.18 | $222.49 |
| Resistance Level | $31.20 | N/A |
| Average True Range (ATR) | 1.44 | 7.60 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 66.95 | 63.40 |
Price Performance
Historical ComparisonAbout CSGP CoStar Group Inc.
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.